{"classes":[{"categories":[{"measurements":[{"comment":"The 95% confidence interval was not estimable as no one was censored so the numbers are actuals and not estimates.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"6.090"},{"comment":"The 95% confidence interval was not estimable as no one was censored so the numbers are actuals and not estimates.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"6.840"},{"comment":"The 95% confidence interval was not estimable as no one was censored so the numbers are actuals and not estimates.","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"3.420"},{"groupId":"OG003","lowerLimit":".000","upperLimit":"27.761","value":"13.130"},{"groupId":"OG004","lowerLimit":"3.580","upperLimit":"15.300","value":"9.440"},{"groupId":"OG005","lowerLimit":"14.072","upperLimit":"33.828","value":"23.950"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"15"}],"units":"Participants"}],"description":"* For participants with confirmed tumor responses\n* A confirmed response is defined to be a complete response (CR), very good partial response (VGPR), or partial response (PR) per IMWG Criteria","dispersionType":"95% Confidence Interval","groups":[{"description":"Dose Level 0: Carfilzomib IV (20 mg/m2) D1\\&D2 of C1 and carfilzomib IV (27 mg/m2)D8, D9, D15, D16 of C1. Carfilzomib IV (27 mg/m2) D1, D2, D8, D9, D15, D16 C2-6. Carfilzomib IV (27 mg/m2)D1, D2, D8, D15, D22 C7+. PLD IV (30 mg/m2)D8 C1-6.","id":"OG000","title":"Phase I - Part 1 Dose Level 0 (Carfilzomib 20/27 mg/m^2)"},{"description":"Dose Level 1: Carfilzomib IV (20 mg/m2) D1\\&D2 of C1 and carfilzomib IV (36 mg/m2)D8, D9, D15, D16 of C1. Carfilzomib IV (36 mg/m2) D1, D2, D8, D9, D15, D16 C2-6. Carfilzomib IV (36 mg/m2)D1, D2, D8, D15, D22 C7+. PLD IV (30 mg/m2)D8 C1-6.","id":"OG001","title":"Phase I - Part 1 Dose Level 1 (Carfilzomib 20/36 mg/m^2)"},{"description":"Dose Level 2: Carfilzomib IV (20 mg/m2) D1\\&D2 of C1 and carfilzomib IV (45 mg/m2)D8, D9, D15, D16 of C1. Carfilzomib IV (45 mg/m2) D1, D2, D8, D9, D15, D16 C2-6. Carfilzomib IV (45 mg/m2)D1, D2, D8, D15, D22 C7+. PLD IV (30 mg/m2)D8 C1-6.","id":"OG002","title":"Phase I - Part 1 Dose Level 2 (Carfilzomib 20/45 mg/m^2)"},{"description":"Dose Level 3: Carfilzomib IV (20 mg/m2) D1\\&D2 of C1 and carfilzomib IV (56 mg/m2)D8, D9, D15, D16 of C1. Carfilzomib IV (56 mg/m2) D1, D2, D8, D9, D15, D16 C2-6. Carfilzomib IV (56 mg/m2)D1, D2, D8, D15, D22 C7+. PLD IV (30 mg/m2)D8 C1-6.","id":"OG003","title":"Phase I - Part 1 Dose Level 3 (Carfilzomib 20/56 mg/^2)"},{"description":"Cohort 0: Carfilzomib IV (56 mg/\\^2 - Phase 1 Part 1) D1, D2, D8, D9, D15, D16 C1-6. Carfilzomib IV (56 mg/m\\^2 - Phase 1 Part 1) D1, D8, D15, D22 C7 and subsequent cycles. PLD IV (30 mg/m\\^2 - Phase 1 Part 1) D8 of each cycle. Dexamethasone 20 mg IV or PO same schedule as carfilzomib.","id":"OG004","title":"Phase I-Part 2 Cohort 0 (Carfilzomib 56 mg/m^2+Dexamethasone)"},{"description":"Carfilzomib IV (56 mg/\\^2 - Phase 1 Part 1) D1, D2, D8, D9, D15, D16 C1-6. Carfilzomib IV (56 mg/m\\^2 - Phase 1 Part 1) D1, D8, D15, D22 C7 and subsequent cycles. PLD IV (30 mg/m\\^2 - Phase 1 Part 1) D8 of each cycle. Dexamethasone 20 mg IV or PO same schedule as carfilzomib.","id":"OG005","title":"Phase 2 (Carfilzomib 56 mg/m^2+ Dexamethasone)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Through completion of follow-up (median follow-up was 23.3 months)","title":"Median Duration of Overall Response","type":"SECONDARY","unitOfMeasure":"months"}